TABLE 4.
Comparison of protease inhibitor effects on clarithromycin pharmacokineticsa
| Agent | % Clarithromycin increase (90% CI)
|
14-OH-CLARb decrease (90% CI)
|
||
|---|---|---|---|---|
| AUC | Cmax | AUC | Cmax | |
| Saquinavir (1,200 mg every 8 h)c | 45 (17–81) | 39 (10–76) | 24 (5–40) | 34 (14–50) |
| Ritonavir (200 mg every 8 h)d | 77 (56–103) | 31 (15–51) | 100 | 99 |
| Indinavir (800 mg every 8 h)e | 53 ± 36f | NSg | 52 | NS |
| Amprenavir (1,200 mg BID)h | No effect | −10 | 35 | 32 |
a
Results are expressed as percent change from values with clarithromycin alone.
b
14-OH-CLAR, 14-(R)-hydroxyclarithromycin.
c
Data are from saquinavir prescribing information (Roche Laboratories).
d
Data are from ritonavir prescribing information (Abbott Laboratories).
e
Data are from indinavir prescribing information (Merck and Company Pharmaceuticals).
f
Mean ± standard deviation.
g
NS, not stated.
h
Data are from this study. BID, twice a day.